Bergen, 30 July 2007; NorDiag is in a letter from Arbeids- og Velferdsdirektoratet (NAV) informed that the public reimbursement of the Company`s Genefec test will be discontinued from September 1.

NAV`s decision will have no consequences for NorDiag`s development program. However, it can have an influence on sales in Norway of the diagnostic product short term.

NorDiag will, in collaboration with its partner Capio, investigate what considerations and procedure regarding NAV`s decision and The Company will present an evaluation of the consequences for the further development of the diagnostic test when presenting Q2 financials at August 16.

NorDiag`s Genefec test is a genetic test for detection of colorectal cancer which to day can be used as an alternative to the FOBT test. The product has until now been marketed in Scandinavia. The Company has a targeted activity to develop the test, both with including new genetic markers and secure clinical documentation. There has been established extensive cooperation with hospitals, laboratories and other diagnostic companies to develop products with necessary documentation and quality. The strategic goal is to design a screening test for colorectal cancer to be introduced when European governments decide this.

Contact person:
CEO Mårten Wigstøl
Mobile: + 47 911 657 75

About NorDiag ASA:
NorDiag is a biotechnology company with focus on gene based diagnostics in the fields of cancer and infectious diseases. The Company`s first product in cancer diagnosis is Genefec TM for diagnosis of colorectal cancer. The company has other applications for diagnosis of cancer under development, among others a screening product for colorectal cancer. In addition the company has a product for automated sample preparation of sexually transmitted diseases, as well as applications for other infectious diseases in the product pipeline. NorDiag is listed at Oslo Stock Exchange with the ticker NORD. www.nordiag.no